APR 16, 2019 09:18 AM PDT

Drug Reduces Risk of Kidney Failure in Type 2 Diabetics

WRITTEN BY: Nouran Amin

A recent breakthrough clinical trial involving 4,401 participants in 34 countries revealed that a particular drug--canagliflozin, for Type 2 diabetics, lowered the risk of kidney failure and kidney disease. The trial, known as CREDENCE, also revealed that canagliflozin reduced the risk of major cardiovascular events. Findings of the CREDENCE trial were published in The New England Journal of Medicine.

"For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure," said Kenneth Mahaffey, MD, professor of medicine at the Stanford University School of Medicine and co-principal investigator of the trial. "Now, patients with diabetes have a promising option to guard against one of the most severe risks of their condition."

Canagliflozin is currently the only FDA approved therapeutic to protect kidney function in people with Type 2 diabetes as well as to reduce their risk of major adverse cardiovascular events. The drug works by increasing the excretion of glucose through the kidneys. It has already been approved by the Food and Drug Administration to lower blood glucose in patients with Type 2 diabetes and to reduce the risk of major adverse cardiovascular events in patients with Type 2 diabetes and existing heart disease.

"A drug like canagliflozin that improves both cardiovascular and renal outcomes has been eagerly sought by both patients with Type 2 diabetes and clinicians caring for them," Mahaffey said.

Individuals living with diabetes are prone to developing kidney disease due to prolonged high blood sugar which harms the blood vessels in the kidney. Additionally, diabetes can lead to high blood pressure, which stretches and weaken blood vessels in the organ.

Learn more on how diabetes can affect the kidneys: 

"People with diabetes and kidney disease are at extremely high risk of kidney failure, heart attack, stroke and death," says lead author of the study, Vlado Perkovic, MBBS, PhD, who is also the executive director of The George Institute for Global Health Australia and a professor of medicine at the University of New South Wales in Sydney. "With this definitive trial result, we now have a very effective way to reduce this risk using a once-daily pill."

Source: Stanford Medicine

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 22, 2019
Genetics & Genomics
NOV 22, 2019
Can Lifestyle Changes Switch Off Dementia Genes?
Around 50 million people have dementia worldwide, with 10 million new cases emerging each year (World Health Organization: 2019). Most prominent in people ...
NOV 22, 2019
Cannabis Sciences
NOV 22, 2019
CBD Alleviates Angelman Syndrome Seizures in Mice Trial
CBD has already been shown to be effective as an anti-anxiety, antipsychotic and anti-epileptic substance. Can it help youth and adults with a rare neurolo...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Common Therapeutic Can Treat Bleeding Associated with Traumatic Brain Injury
An inexpensive and accessible drug was found to reduce rates of mortality associated with traumatic brain injury (TBI) patients by 20%. TBI is a major caus...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
Novel Therapeutic For Eradicating The Flu Virus
Public Health officials have long warned about pandemic pathogens flying fast around the world. One virus already spreads across the globe annually leading...
NOV 22, 2019
Cancer
NOV 22, 2019
How caloric restriction mimetics might prove helpful for cancer treatments
The benefits of fasting have been known to scientists and medical professionals for some time now, however for many, the reality of fasting is not alluring...
NOV 22, 2019
Drug Discovery & Development
NOV 22, 2019
The Side-Effects to A Common Blood Cancer Drug
In a study published in Scientific Reports, a popular cancer drug, known as ruxolitnib, was found to cause an increased weight gain as well as an increase ...
Loading Comments...